Zuk Aleksandra, Fitzpatrick Tiffany, Rosella Laura C
Dalla Lana School of Public Health, Division of Epidemiology, University of Toronto, Toronto, Ontario, Canada.
Public Health Ontario, Toronto, Ontario, Canada.
PLoS One. 2016 Apr 26;11(4):e0154215. doi: 10.1371/journal.pone.0154215. eCollection 2016.
Obesity induced low-grade chronic inflammation disrupts proper immune and metabolic function. Vitamin D deficiency increases inflammation, which is associated with cardiometabolic risk. This systematic review examines the association between oral vitamin D (VD) supplementation and circulating inflammatory biomarkers and glycemic outcomes from randomized controlled trials (RCTs) of overweight and/or obese adults.
MEDLINE OVID, EMBASE and the Cochrane Central Register of Controlled Trials were searched according to a predefined protocol. Eligible RCTs included adults randomized to receive either oral VD or placebo. Two reviewers independently assessed RCTs for inclusion. Bias was assessed using the Cochrane Collaboration risk of bias tool. Mean differences were calculated comparing end-of-study sample means between the independent VD and placebo groups.
Eleven unique RCTs met inclusion criteria from a total of 3,383 identified citations, including 79 screened articles and 14 full text data extractions. Inflammatory and glycemic measures were reported in 7 and 10 RCTs, respectively. Most trial findings were non-significant with considerable heterogeneity in design, participants and outcomes. All but one trial was rated as either high or unclear risk of bias. Two RCTs reported significant changes in inflammatory biomarkers; however, the mean difference between groups was not statistically significant: C-reactive protein 0.19 mg/L (p = 0.88); Tumor Necrosis Factor -0.54 pg/ml (p = 0.20). Two other trials found significant mean differences in fasting plasma glucose -0.32 mmol/L (p = 0.03), Hemoglobin A1c -0.13% (p = 0.04), and Homeostatic Model Assessment -0.86 (p = 0.02) following VD supplementation.
Overall, there is no clear established benefit of VD supplementation on inflammatory biomarkers among overweight/obese adults. Baseline serum VD possibly influences the effect of VD repletion on inflammatory markers. Risk of bias was present in most studies, thus supporting the need for higher quality studies in this area to more conclusively understand the role VD supplementation has on inflammatory pathways.
肥胖引发的低度慢性炎症会扰乱正常的免疫和代谢功能。维生素D缺乏会加剧炎症,而炎症与心血管代谢风险相关。本系统评价旨在研究超重和/或肥胖成年人的随机对照试验(RCT)中,口服维生素D(VD)补充剂与循环炎症生物标志物及血糖结果之间的关联。
按照预定义方案检索MEDLINE OVID、EMBASE和Cochrane对照试验中央注册库。符合条件的RCT包括随机接受口服VD或安慰剂的成年人。两名评价者独立评估RCT是否纳入。使用Cochrane协作偏倚风险工具评估偏倚。计算独立VD组和安慰剂组研究结束时样本均值的平均差异。
从总共3383条已识别的文献中,有11项独特的RCT符合纳入标准,包括79篇筛选文章和14篇全文数据提取。分别有7项和10项RCT报告了炎症和血糖指标。大多数试验结果无统计学意义,在设计、参与者和结果方面存在相当大的异质性。除一项试验外,所有试验的偏倚风险均被评为高或不清楚。两项RCT报告炎症生物标志物有显著变化;然而,组间平均差异无统计学意义:C反应蛋白0.19mg/L(p = 0.88);肿瘤坏死因子-0.54pg/ml(p = 0.20)。另外两项试验发现补充VD后空腹血糖平均差异有统计学意义-0.32mmol/L(p = 0.03),糖化血红蛋白-0.13%(p = 0.04),稳态模型评估-0.86(p = 0.02)。
总体而言,超重/肥胖成年人补充VD对炎症生物标志物没有明确的既定益处。基线血清VD可能会影响VD补充对炎症标志物的作用。大多数研究存在偏倚风险,因此支持在该领域开展更高质量研究的必要性,以便更确切地了解补充VD在炎症途径中的作用。